What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
His main research concerns Cancer research, Immunology, Lung cancer, Immune system and Internal medicine.
His Cancer research research includes themes of Cell growth, Mutation, Gene, Gefitinib and TGF beta 1.
In Immunology, David P. Carbone works on issues like Cancer, which are connected to Cell culture.
David P. Carbone has included themes like Carcinogenesis, Carcinoma, Docetaxel and Adenocarcinoma in his Lung cancer study.
His Immune system research is multidisciplinary, incorporating elements of Vascular endothelial growth factor A, Cytotoxic T cell and Stem cell.
The various areas that he examines in his Internal medicine study include Endocrinology, Gene rearrangement and Oncology.
His most cited work include:
- Comprehensive genomic characterization of squamous cell lung cancers (2590 citations)
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. (1576 citations)
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. (1576 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Lung cancer, Cancer research, Internal medicine, Oncology and Cancer.
His Lung cancer research incorporates elements of Carcinoma, Disease and Epidermal growth factor receptor.
As part of the same scientific family, David P. Carbone usually focuses on Cancer research, concentrating on Immunology and intersecting with Cytotoxic T cell.
His Internal medicine study frequently links to other fields, such as Endocrinology.
His Oncology research includes elements of Surgery, Nivolumab, Clinical trial and Lung.
His Immune system study combines topics from a wide range of disciplines, such as Vascular endothelial growth factor and Notch signaling pathway.
He most often published in these fields:
- Lung cancer (42.91%)
- Cancer research (42.91%)
- Internal medicine (39.27%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (39.27%)
- Oncology (32.76%)
- Cancer research (42.91%)
In recent papers he was focusing on the following fields of study:
David P. Carbone mainly investigates Internal medicine, Oncology, Cancer research, Lung cancer and Immunotherapy.
His work carried out in the field of Oncology brings together such families of science as Pembrolizumab, Atezolizumab, Cancer and First line.
His Cancer study incorporates themes from Microbiome and Melanoma.
His Cancer research research incorporates themes from Exome sequencing, CD8, Immune system and Tyrosine-kinase inhibitor.
His work in Lung cancer addresses subjects such as Point mutation, which are connected to disciplines such as Somatic cell and KRAS.
His work on Immune checkpoint inhibitors as part of general Immunotherapy study is frequently linked to Center, therefore connecting diverse disciplines of science.
Between 2018 and 2021, his most popular works were:
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study (77 citations)
- Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). (56 citations)
- Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. (51 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
David P. Carbone mostly deals with Internal medicine, Lung cancer, Oncology, Cancer research and Immunotherapy.
His research integrates issues of Mutation, Gene, Regimen and Clinical trial in his study of Lung cancer.
His Oncology research is multidisciplinary, incorporating perspectives in Biomarker, Randomized controlled trial, Atezolizumab and Lung.
His study in Cancer research is interdisciplinary in nature, drawing from both Cell, T cell immunity, Immune system, Kinase and Programmed cell death.
His Immune system study integrates concerns from other disciplines, such as Cytotoxic T cell, Antibody and microRNA, Circulating MicroRNA.
David P. Carbone has researched Immunotherapy in several fields, including Microbiome, Concomitant, Antibiotics and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
